
Amplia Therapeutics Limited
ASX:ATX.AX
Overview | Financials
Company Name | Amplia Therapeutics Limited |
Symbol | ATX.AX |
Currency | AUD |
Price | 0.084 |
Market Cap | 32,588,052 |
Dividend Yield | 0% |
52-week-range | 0.055 - 0.18 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. |
Website | https://www.ampliatx.com |
An error occurred while fetching data.
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD